Jiu Zhi Tang: Net profit of 223 million yuan in 2025, gradually exploring the layout of innovative businesses such as stem cells

Recently, Jiuzhitang announced its 2025 annual report, with a total operating revenue of 2.23 billion yuan, a year-on-year decrease of 6.0%; net profit attributable to shareholders was 223 million yuan, a year-on-year increase of 3.0%; net profit attributable to shareholders after deducting non-recurring gains and losses was 191 million yuan, a year-on-year increase of 4.1%; net operating cash flow was 426 million yuan, a year-on-year increase of 114.3%; EPS (fully diluted) was 0.2601 yuan.

In the fourth quarter, the company’s operating revenue was 602 million yuan, a year-on-year increase of 95.5%; net profit attributable to shareholders successfully turned around from a loss of 24.1 million yuan in the same period last year to a net profit attributable to shareholders of 71.07 million yuan; net profit attributable to shareholders after deducting non-recurring gains and losses turned around from a loss of 33.5 million yuan in the same period last year to a net profit of 59.79 million yuan; EPS was 0.083 yuan.

As of the end of the fourth quarter, the company’s total assets were 5.436 billion yuan, an increase of 4.3% compared to the end of the previous year; net assets attributable to shareholders were 3.722 billion yuan, a decrease of 0.8% compared to the end of the previous year.

In its 2025 annual report, the company mentioned that its operating business has maintained stable growth, with no significant changes. During the reporting period, the company continued to promote its core businesses in traditional Chinese medicine research and development, production, and sales, while gradually exploring innovative businesses such as stem cells, traditional Chinese medicine health services, and series of health products derived from food and medicine.

The announcement stated that the company’s progress in the stem cell project and core products like YB209 and YB211 is in line with expectations, and its innovative momentum is continuously strengthening. In addition, the company is extending its industrial chain and enhancing collaborative value through strategic investments and acquisitions in the peptide sector by holding Jixiang Long. The report also emphasized that subsidiaries such as Youbo Pharmaceutical, SciGen, and Hainan Pharmaceutical are steadily advancing their business development in their respective fields, ensuring overall operational synergy and enhancement.

(Jiuzhitang Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords:

                                                            Healthcare